Developing Oncolytic Viruses
into Cancer Therapeutics
Oncos Therapeutics develops novel cancer therapies based on its next generation oncolytic viruses.
Since the onset of our Advanced Therapy Access Program in 2007, 200 patients have undergone tailored treatment suggesting strong safety and efficacy. The program is based on extensive scientific research at the University of Helsinki and serves as the foundation for our ongoing clinical development.
Our next generation oncolytic viruses put tumors to work for medication:
- Replication in cancer cells. 1 virus replicates to 10,000, simultaneously killing the host cancer cell. The 10,000 new viruses seek to enter and replicate again in new cancer cells, killing them while leaving normal healthy cells unharmed.
- Anti-tumor immune response. Both the oncolysis and the presence of adenoviruses in tumors are strong danger signals to the immune system, mediating significant natural immunologic response against the tumor.
- Fighting metastases: Virus replicas circulate in the blood stream to find new metastases, where further replication and local anti-tumor immunologic response continue to fight the disease.